Rexahn Pharmaceuticals to Present Data on Novel Anti-Cancer Small Molecule RX-8243 at the American Association for Cancer Research
ROCKVILLE, Md.--(BUSINESS WIRE)--Apr 15, 2010 - Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system (CNS) therapeutics, today announced that it will present pre-clinical data on its anticancer compound RX-8243 at the American Association for Cancer Research (AACR) 101st Annual Meeting, held in Washington, D.C., April 17-21, 2010, at the Walter E. Washington Convention Center.
These data on the anti-cancer activity of RX-8243 will be presented in a poster (abstract #3562) entitled, “Characterization of a novel small molecule with potent anticancer activity,” on Tuesday, April 20, 2010, from 9:00 am – 12:00 pm EDT in Exhibit Hall A-C, Poster Section 24, during the “Experimental and Molecular Therapeutics” session.
For more information on the AACR conference, please visit www.aacr.org.
RX-8243 is a novel isoquinolinamine analogue that inhibits Ark1 (Aurora A) kinase and other Ser/Thr kinases implicated in cancer progression. RX-8243 is a multikinase inhibitor that down-regulates signal molecules of RAS as well as PI3K pathways such as activated forms of ERK, p38 and Akt. Pre-clinical studies demonstrated that RX-8243 blocked tumor growth in xenograft models at low nanomolar concentrations. These studies also have shown RX-8243 to be more effective against paclitaxel, gemcitabine and cisplatin-resistant cancer cell lines when compared to the original cytotoxic cancer drugs. RX-8243 is part of a robust pipeline of pre-clinical anti-cancer compounds that Rexahn has developed to provide higher efficacy and to improve the quality of life and survival of patients.
About Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals is a clinical stage pharmaceutical company dedicated to commercializing first in class and market leading therapeutics for cancer, CNS disorders, sexual dysfunction and other unmet medical needs. Rexahn currently has three drug candidates in Phase II clinical trials, Archexin®, Serdaxin®, and Zoraxel™ - all potential best in class therapeutics - and a robust pipeline of preclinical compounds to treat multiple cancers and CNS disorders. Rexahn also operates key R&D programs of nano-medicines, 3D-GOLD, and TIMES drug discovery platforms. For more information, please visit www.rexahn.com.
This press release contains forward-looking statements. Rexahn's actual results may differ materially from anticipated results, and expectations expressed in these forward-looking statements, as a result of certain risks and uncertainties, including Rexahn's lack of profitability, and the need for additional capital to operate its business to develop its product candidates; the risk that Rexahn's development efforts relating to its product candidates may not be successful; the possibility of being unable to obtain regulatory approval of Rexahn's product candidates; the risk that the results of clinical trials may not be completed on time or support Rexahn's claims; demand for and market acceptance of Rexahn's drug candidates; Rexahn's reliance on third party researchers and manufacturers to develop its product candidates; Rexahn's ability to develop and obtain protection of its intellectual property; and other risk factors set forth from time to time in our filings with the Securities and Exchange Commission. Rexahn assumes no obligation to update these forward-looking statements.
Contact: Rexahn Pharmaceuticals, Inc.
Stern Investor Relations, Inc.
Stephanie Ascher, 212-362-1200
Base Pair Communications
Constantine Theodoropulos, 617-401-3116
Posted: April 2010